Intrinsic pro-angiogenic status of cystic fibrosis airway epithelial cells by Verhaeghe, Catherine et al.
www.elsevier.com/locate/ybbrc
Biochemical and Biophysical Research Communications 356 (2007) 745–749Intrinsic pro-angiogenic status of cystic ﬁbrosis airway
epithelial cells q,qq
Catherine Verhaeghe a,1, Sebastien P. Tabruyn b,1, Cecile Oury a, Vincent Bours a,*,2,
Arjan W. Griﬃoen b,2
a Unit of Human Genetics, GIGA-Research, University of Lie`ge, Belgium
b Department of Pathology, Angiogenesis Laboratory, GROW, University of Maastricht, The Netherlands
Received 22 February 2007
Available online 16 March 2007Abstract
Cystic ﬁbrosis is a common genetic disorder characterized by a severe lung inﬂammation and ﬁbrosis leading to the patient’s death.
Enhanced angiogenesis in cystic ﬁbrosis (CF) tissue has been suggested, probably caused by the process of inﬂammation, as similarly
described in asthma and chronic bronchitis. The present study demonstrates an intrinsic pro-angiogenic status of cystic ﬁbrosis airway
epithelial cells. Microarray experiments showed that CF airway epithelial cells expressed several angiogenic factors such as VEGF-A,
VEGF-C, bFGF, and PLGF at higher levels than control cells. These data were conﬁrmed by real-time quantitative PCR and, at the
protein level, by ELISA. Conditioned media of these cystic ﬁbrosis cells were able to induce proliferation, migration and sprouting
of cultured primary endothelial cells. This report describes for the ﬁrst time that cystic ﬁbrosis epithelial cells have an intrinsic angiogenic
activity. Since excess of angiogenesis is correlated with more severe pulmonary disease, our results could lead to the development of new
therapeutic applications.
 2007 Elsevier Inc. All rights reserved.
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ﬁbrosis transmembrane conductance regulator (CFTR)
gene and is the most common life-shortening genetic disor-
der among caucasians. While diﬀerent organs are aﬀected
in CF patients, chronic lung disease and ﬁbrosis are the
most severe clinical manifestations leading to the patient’s0006-291X/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.bbrc.2007.02.166
q C.V. was supported by a F.R.I.A. (‘‘Fond pour la recherche
industrielle et agricole’’) and by a ‘Fondation Leon Fredericq’ fellowships.
S.P.T. and A.W.G. was supported by a Senter/Novem Fellowship. C.O. is
a Research Associate of the F.N.R.S (Belgium).
qq A major role for IKK and ERK pathways in intrinsic inﬂammation of
cystic ﬁbrosis airways. Verhaeghe C., Remouchamps C., Vanderplasschen
A., Hennuy B., Chariot A., Tabruyn SP, Oury C., Bours V. Biochemical
Pharmacology. In Revision.
* Corresponding author. Fax: +32 4 366 81 46.
E-mail address: vbours@ulg.ac.be (V. Bours).
1 These authors contributed equally to this work.
2 These authors share equal responsibility in this work.death [1]. While inﬂammation is recognized as the driving
force leading to ﬁbrosis, increasing evidence also supports
the contribution of vascular remodeling in pulmonary
ﬁbrosis [2]. Angiogenesis, the formation of new blood ves-
sels from pre-existing ones, is linked to many pathologies
characterized by lung inﬂammation (asthma, chronic
obstructive pulmonary disease or idiopathic pulmonary
ﬁbrosis) and contributes to maintain a chronic inﬂamma-
tory state [3,4]. New vessels facilitate the diapedesis of
inﬂammatory cells and produce a signiﬁcant source of
pro-inﬂammatory cytokines. Signs of excessive angiogene-
sis have been already reported in CF patients who develop
highly vascularized nasal polyps requiring surgical resec-
tion. In addition, angiogenesis-related complications, such
as pulmonary hemorrhage and hemoptysis commonly
occur in CF patients [5]. In addition, a previous report
has shown higher levels of vascular endothelial growth
factor (VEGF) in the serum of CF patients than in other
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correlated with a more severe pulmonary disease [6]. The
production of VEGF, as well as the induction of angiogen-
esis, is commonly interpreted as a consequence of the
inﬂammation process.
In this paper, we describe the overproduction of potent
pro-angiogenic factors in human epithelial fetal tracheal
cells (CF cells), originating from a cystic ﬁbrosis fetus, as
compared to control cells. This production is suﬃcient to
stimulate angiogenesis. Our results thus suggest that an
intrinsic pro-angiogenic status of CF airway epithelial cells,
contributes to enhanced angiogenesis and clinical
symptoms.
Materials and methods
Cell culture. Immortalized human fetal tracheal cells (CFT-2, cell line
carrying the homozygous mutation DF508, and NT-1, control cell line)
were previously characterized [7,8]. Human umbilical vein endothelial cells
(HUVEC) were isolated and cultured as previously described [9]. Only
cells from passage 1 to 3 were used for experiments.
Real-time RT-PCR. Real-time PCR was carried out on a TaqMan
platform using SYBR Green reagent (Applied Biosystems, Foster city,
CA) as described previously [10]. Primers were designed using the Primer
Express software (Applied Biosystems). Transcript levels were normalized
using the housekeeping gene b2-microglobulin.
ELISA. Concentrations of VEGF in NT-1 and CFT-2 supernatants
were determined by the ‘Quantikine human VEGF’ immunoassay
according to the manufacturer’s recommendations (R&D Systems).
Proliferation assay. HUVECs were seeded at 5000 cells/well in gelatin-
coated ﬂat-bottomed 96-well tissue culture plates and grown for 3 days in
culture medium supplemented with 0.1% FCS and various volume of NT1
or CFT2 supernatant. On the third day, BrdU was added and incorpo-
ration was allowed to occur for 18 h. After harvesting the cells, BrdU
incorporation was quantiﬁed using the Cell Proliferation Biotrak ELISA
system (Amersham Biosciences) according to the manufacturer’s
recommendations.
Migration assay. Migration assays were carried on as previously
described [11]. Brieﬂy, HUVEC cultures were grown to conﬂuency in
gelatin-coated 24-well tissue culture plates. A cross-shape wound was
made by scratching the monolayer with a plastic tip. Wounded mono-Fig. 1. Validation of diﬀerential regulation of angiogenesis-related genes and p
and transcript expression levels of VEGF-A, VEGF-C, PLGF and THSP1 wer
gene expression in CFT-2 (CF) cells relative to NT-1 (control) cells. Data are
representative of at least three distinct experiments. *p < 0.05 and **p < 0.005 vs
of NT-1 and CFT-2 cells. Data are expressed in ng/ml of conditioned media
(10 lM) prior to RNA extraction and determination of transcript expression. D
control NT-1 cells. *p < 0.05. Each column represents the means ± SD (n = 3)layers were washed with PBS and incubated with fresh culture medium
supplemented with 0.1% FCS and various volume of NT1 or CFT2
supernatant. The wound width was measured microscopically at four
diﬀerent places 0, 2, 4, and 6 h after wounding the culture.
Sprouting assay. HUVEC were suspended in culture medium and
seeded on non-adherent plates. The suspended cells integrate into a single
spheroid of deﬁned size and cell number. After 24 h of incubation at 37 C,
the spheroids were embedded in a collagen gel and treated with the dif-
ferent conditioned media. Quantiﬁcation was performed by digital imag-
ing and calculating length of the spheroid sprouts after 8 h of incubation
with the conditioned media. At least 10 spheroids per group and experi-
ment were analyzed.
Statistical analysis. Data are expressed as mean values ± SEM and
were analyzed by a Student’s t-test. Diﬀerences are considered signiﬁcant
at p 6 0.05.Results
CF cells diﬀerentially express angiogenic genes
Our previous gene expression proﬁle analysis indicated
overexpression of several pro-inﬂammatory molecules in
CF epithelial cells compared to control epithelial cells
(see Footnoteqq). The list of diﬀerentially regulated genes
between CF and control cells has been further investigated
with Ingenuity Systems Pathways (Ingenuity Systems). In
addition to genes described to play a role in both inﬂamma-
tion and angiogenesis, such as interleukin-8 (IL-8), this
analysis highlighted up-regulation of numerous pro-angio-
genic genes in CF cells, namely basic ﬁbroblast growth fac-
tor (bFGF), ﬁbroblast growth factor 5, placental growth
factor (PGF), platelet-derived growth factor-C, platelet-
derived growth factor-a polypeptide, angiopoietin 1,
VEGF-A, and VEGF-C. In addition, a well-known anti-
angiogenic gene, namely thrombospondin-1 (THSP1),
was found to be down-regulated in CF compared to con-
trol cells.
Diﬀerential expression of four selected genes was then
conﬁrmed by real-time RT-PCR (Fig. 1A). The expressionroteins in CF cells. (A) RNAs from NT-1 and CFT-2 cells were extracted
e analyzed by real-time RT-PCR. Values are expressed as fold increase in
normalized by quantiﬁcation of the b2 microglobulin transcripts and are
. NT-1. (B) Quantiﬁcation by ELISA of VEGF production in supernatants
. **p < 0.005 vs. NT-1. (C) CFT-2 cells were treated for 6 h with U1026
ata are expressed as fold increase in gene expression of CF cells relative to
.
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and PLGF was signiﬁcantly up-regulated in CF cells as
compared to control cells (by 1.6-, 1.9-, and 2.0-fold, respec-
tively), while the expression of the anti-angiogenic THSP1
transcript was decreased by about 10-fold in CF cells in
comparison to control cells. ELISA tests conﬁrmed a 8-fold
higher production of VEGF-A by CF cells, a protein known
for its central role in angiogenesis (Fig. 1B) [12].
Involvement of ERK in pro-angiogenic gene up-regulation in
CF cells
In a previous work, we demonstrated a constitutive
AP-1 activation in CF epithelial cells. Furthermore, we
demonstrated that ERK1/2 signaling contributes to the
overexpression of pro-inﬂammatory genes (see Footnote
qq). To determine if ERK1/2 is also involved in the up-
regulation of the pro-angiogenic genes, CF cells were trea-
ted with the speciﬁc inhibitor of MEK1 (ERK kinase),
U0126. The expression of the three selected up-regulated
genes was signiﬁcantly reduced in the presence of U1026
(Fig. 1C) while down-regulation of THSP1 was not aﬀected
(Fig. 1C). These data suggest that part of the pro-angio-
genic status of CF epithelial cells depends on the activation
of the ERK1/2 pathway.
CF cells induce proliferation of endothelial cells
Since CF cells express various potent angiogenic factors,
we analyzed the pro-angiogenic properties of conditioned
media. Conditioned media from CF and control epithelial
cells were collected and tested for their ability to induce
proliferation of HUVECs. Endothelial cells stimulated
with various dilutions of CF cell conditioned media dis-Fig. 2. Induction of endothelial cells proliferation by CF cells. Prolifer-
ation of endothelial cells was determined by monitoring DNA synthesis.
HUVEC were stimulated for 48 h with various dilutions of CF or control
conditioned media and assessed for their ability to incorporate BrdU.
BrdU incorporation was then measured by ELISA. Each column
represents the means ± SD (n = 3). *p < 0.05 vs. NT-1.played a higher proliferation rate than control cells, as
measured by incorporation of BrdU (Fig. 2).
CF cells induce migration of endothelial cells
The eﬀect of conditioned media on endothelial cell
migration was then measured by a wound assay. Migration
of endothelial cells into the wounded area was signiﬁcantly
increased in the presence of CF conditioned media as com-
pared to control conditioned media. This eﬀect was already
visible as early as 2 h after wounding and was signiﬁcantly
diﬀerent from the control after 4 and 6 h (Fig. 3A). In addi-
tion, after 6 h, the migration was inhibited by diluting the
CF conditioned media (Fig. 3B), which is indicative of a
dose dependent eﬀect.
CF cells induce sprouting of endothelial cells
HUVEC spheroids seeded into a collagen gel in the
presence of angiogenic stimuli have the ability to sproutFig. 3. Induction of endothelial cells migration by CF cells. Migration of
endothelial cells was determined by wound assays. Conﬂuent HUVEC
cultures were wounded and treated with CF or control conditioned media.
Subsequently, wound width was measured at 2, 4, and 6 h (A). Wound
width of HUVEC cultures treated with diﬀerent dilutions of conditioned
media was also analyzed at 6 h after wounding (B). Data are represen-
tative of at least three distinct experiments. Each bar represents the
means ± SD, n = 3. *p < 0.05 and **p < 0.005 vs. WT.
Fig. 4. Induction of endothelial cells sprouting by CF cells. In vitro
angiogenesis was determined using sprouting assay based on collagen
embedded HUVEC spheroids. Spheroids were embedded into collagen
and photographed before (A,B) and 8 h (C,D) after incubation with WT
(A–C) or CF (B,D) cells conditioned media. (E) For each experiment, at
least 10 spheroids per group were analyzed and cumulative spheroids
length was measured. Data are representative of at least three distinct
experiments. Each bar represents the mean ± SD, n = 3. *p < 0.05 vs. WT.
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investigated the eﬀects of CF cell conditionedmedia in a col-
lagen-gel-based sprout assay. Fig. 4A–D show representa-
tive pictures of spheroids before (A and B) and after an
8 h-treatment with control (A and C) and CF (B and D)
conditioned media. A higher percentage of spheroids was
found to sprout in the presence of CF than in the presence
of control conditioned media (62% vs. 35%). Quantitative
assessment of this in vitro angiogenesis assay was achieved
by measuring the size of the capillary sprouts out of the
spheroids. The cumulative sprout length was found to be
signiﬁcantly increased for the spheroids treated with CF cell
conditioned media (Fig. 4E).Discussion
Although angiogenesis has been associated with cystic
ﬁbrosis, the literature on this subject is really sparse. Theonly available data described an excess of angiogenesis in
CF polyps and elevated levels of VEGF in the serum of
cystic ﬁbrosis patients [5,6]. Angiogenesis and vascular
remodeling are key elements participating in tissue
remodeling in various chronic airway inﬂammatory dis-
eases such as asthma and chronic bronchitis [4,13]. Such
alterations in the microvasculature largely contribute to
the pathophysiology of chronic inﬂammatory airway dis-
eases. The origin of angiogenesis in the lung of CF
patients is controversial. It was generally considered that
the abnormal mucus favors infections and lung coloniza-
tion by bacteria, which in turn leads to a chronic inﬂam-
mation and subsequent angiogenesis [14,15]. However,
several recent ﬁndings from our and other groups suggest
that some degree of inﬂammation could be observed in
CF cells or lungs even before any infection [16–19].
Our results newly show that human epithelial fetal tra-
cheal cells carrying the homozygous CFTR mutation
DF508 display a pro-angiogenic state compared to con-
trol epithelial cells. This pro-angiogenic state is charac-
terized by the increased production of VEGF-A but
also by the upregulation of at least 10 genes encoding
diﬀerent pro-angiogenic factors such as VEGF-C, PLGF,
ANG1, and bFGF. In addition, we observed a down-
regulation of at least one angiostatic agent, namely
thrombospondin-1. These results underline that VEGF
is not the only factor involved in the excess of angiogen-
esis in cystic ﬁbrosis. CF conditioned media were found
to induce several angiogenic function of primary endo-
thelial cells such as proliferation, migration and sprout-
ing. These data suggest that CF epithelial cells could
eﬃciently induce angiogenesis.
Along with the angiogenic process, microvascular
remodeling is known to be a key feature of inﬂammatory
diseases [13]. This process involves structural alterations,
usually enlargement of arterioles, capillaries or venules.
In addition, these remodeled blood vessels have abnor-
malities in endothelial barrier function and are leaky.
The role of the angiopoietin family members has been
demonstrated in the vascular remodeling process occur-
ring in asthma and chronic bronchitis [20,21]. Similarly,
we found that CF epithelial cells express more Ang1
and angiopoietin like-2 than control epithelial cells.
These results raise the possibility that CF epithelial cells
could initiate or increase the inﬂammation-related vascu-
lar remodeling in CF patients.
Although there is still a debate about a pre-existing pro-
inﬂammatory state in CF epithelial cells, our group and
others have demonstrated constitutive activation of two
important transcription factors that play central role in
the onset and persistence of an inﬂammatory process:
NF-jB and AP-1 [16,22–26]. Furthermore, we have shown
a role for the ERK1/2 signaling pathway in pro-inﬂamma-
tory gene expression in CF cells (see Footnote qq). In this
study, using the NF-jB inhibitor BAY 11-7085 and the
speciﬁc inhibitor of MEK1 (ERK kinase), we highlighted
that ERK1/2 pathway, but not the NF-jB pathway (data
C. Verhaeghe et al. / Biochemical and Biophysical Research Communications 356 (2007) 745–749 749not shown), was involved in the expression of pro-angio-
genic genes.
In conclusion, this study reports the ability of CF epi-
thelial cells to intrinsically promote angiogenesis via the
expression of angiogenic factors. Overexpression of diﬀer-
ent pro-angiogenic molecules by CF epithelial cells could
contribute to the alterations of the microvasculature by
increasing angiogenesis but also by inducing microvascular
remodeling. Since angiogenesis is correlated with more
severe pulmonary diseases, therapies based on angiostatic
agents could therefore be eﬃcient to reduce this phenome-
non and to decrease the severity of the CF pathology.
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